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Abstract
Three AKT serine/threonine kinase isoforms (AKT1/AKT2/AKT3) mediate proliferation,
metabolism, differentiation and anti-apoptotic signals. AKT isoforms are activated down-
stream of PI3-kinase and also by PI3-kinase independent mechanisms. Mutations in the
lipid phosphatase PTEN and PI3-kinase that increase PIP3 levels increase AKT signaling in
a large proportion of human cancers. AKT and other AGC kinases possess a regulatory
mechanism that relies on a conserved hydrophobic motif (HM) C-terminal to the catalytic
core. In AKT, the HM is contiguous to the serine 473 and two other newly discovered (serine
477 and tyrosine 479) regulatory phosphorylation sites. In AKT genes, this regulatory HM
region is encoded in the final exon. We identified a splice variant of AKT2 (AKT2-13a),
which contains an alternative final exon and lacks the HM regulatory site. We validated the
presence of mRNA for this AKT2-13a splice variant in different tissues, and the presence of
AKT2-13a protein in extracts from HEK293 cells. When overexpressed in HEK293 cells,
AKT2-13a is phosphorylated at the activation loop and at the zipper/turn motif phosphoryla-
tion sites but has reduced specific activity. Analysis of the human transcriptome correspond-
ing to other AGC kinases revealed that all three AKT isoforms express alternative
transcripts lacking the HM regulatory motif, which was not the case for SGK1-3, S6K1-2,
and classical, novel and atypical PKC isoforms. The transcripts of splice variants of Akt1-3
excluding the HM regulatory region could lead to expression of deregulated forms of AKT.
Introduction
AKT isoforms are activated downstream of PI3-kinase signaling and play both redundant as
well as specific roles in signaling [1]. The phosphatidylinositol-3,4,5-triphosphate (PIP3) sec-
ond messenger at the cell membrane triggers the recruitment of AKT to the membrane
through its N-terminal PH-domain and enables its subsequent activation by its upstream
kinases, PDK1 (Phosphoinositide-dependent kinase-1, which phosphorylates Thr308/T309 in
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the activation loop–numbering residues in AKT1/AKT2, respectively) and mTOR (mechanis-
tic Target of Rapamycin, which phosphorylates Ser473/474 in the hydrophobic motif (HM))
(Fig 1A and 1B) [2]. The C-terminal extension also comprises the T451/T452 turn motif (also
termed “zipper”) which is constitutively phosphorylated in AKTs [3]. Pathological elevation of
PIP3 levels can either be conferred by mutations of PI3-kinase that enhance activity or by
mutations in PTEN, the enzyme that dephosphorylates PIP3 and thus terminates the signal.
Both types of mutations are frequently found in human cancers and enhance AKT phosphory-
lation and downstream signaling. More recently, it was found that additional phosphorylation
sites modify AKT activity (serine 477 and also tyrosine 479 in AKT1) [4]. It has been widely
considered that the activation loop phosphorylation activates AKT many fold while the HM
phosphorylation further enhances the specific activity of AKT, although this is presently con-
tested [4]. Once phosphorylated at the HM and at the activation loop, AGC kinases and in par-
ticular AKTs are activated by the intramolecular interaction of the HM to the PIF-pocket
regulatory site and the concerted action of the activation loop and HM phosphorylation sites
stabilizing the helix α1 and the active site in the proper active conformation (Fig 1C).
AKT activation in response to elevation of PIP3 levels involves the co-localization of AKT
with its upstream kinase PDK1 (Fig 1B). This co-localization occurs via membrane binding
and does not require a docking interaction between the HM and the PIF-pocket of PDK1, an
interaction that is required for the phosphorylation of other substrates of PDK1, i.e. SGK, S6K,
RSK, PKCs, etc. Although not required for activation of AKT by PDK1, in the absence of PIP3,
the HM of AKT can indeed dock to the PIF-pocket of PDK1 [5]; this interaction has also been
confirmed by the crystal structure of the complex between PDK1 and a polypeptide compris-
ing the phosphorylated HM of AKT1 [6]. More recently, additional modes of AKT phosphory-
lation and activation, independently of PI3-kinase activation, have been described [4, 7, 8]. It
is not known if the PI3-kinase independent activation of AKT requires the docking interaction
of the HM to the PIF-pocket of PDK1.
The three AKT isoforms are encoded by three gene loci (AKT1, AKT2 and AKT3). AKT1
null mice show growth problems and perinatal lethality [9], while AKT2-knock-out animals
develop insulin resistance and type 2 diabetes [10, 11]. AKT3 is predominantly expressed in
brain and female tissues.
Fig 1. Activation of AGC kinases. A. The active site of inactive AGC kinases is inaccessible due to intramolecular shielding through the bound PH domain. B.
Translocation to the membrane and binding of PIP2/PIP3 by the PH domain makes the kinase active site accessible for activation by PDK1 (which phosphorylates T308)
and mTOR (which phosphorylates S473 at the hydrophobic motif HM). C. S473 phosphorylation triggers intramolecular binding of the hydrophobic motif (HM)
regulatory site to the PIF pocket and further activation of the kinase by allosteric mechanisms.
https://doi.org/10.1371/journal.pone.0242819.g001
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Alternative splicing is a powerful tool to generate different transcripts and hence distinct
proteins from a single gene [12, 13]. Alternative splicing is abundant in humans and observed
in most genes. Some genes have been shown to produce more “alternatively” spliced tran-
scripts than the transcript(s) considered “regular” [14]. Changes in alternative splicing have
been found to underlie human diseases [15].
Here we identified an alternatively spliced AKT2 transcript produced by activation of a
cryptic exon located in the genes’ final intron. This generates a transcript that encodes an
AKT2 isoform with an alternative C-terminus, which does not possess the HM (Ser474) and
its contiguous Ser478 regulatory phosphorylation sites.
Materials and methods
Reagents, antibodies and cell lines
A 30-residue peptide representing the sequence of the cryptic exon of AKT2 (FREG-
FLEEEANVSAGRRNDVWDASNGRSMA) was generated by FPT Peptide Technologies, Ber-
lin, Germany. The peptide was coupled to LPH (Limulus polyphemus Hemocyanine) and then
used to produce polyclonal rabbit antiserum by BioGenes, Berlin, Germany. Rabbit polyclonal
AKT2 antibody (#9272), anti-phospho Thr308 (#9275), anti-phospho Ser473 (#9271) and anti-
phospho Thr451 (#9267) AKT antibodies were from Cell Signaling (MA, U.S.A.). The human
embryonic kidney cell line HEK293 was maintained in DMEM supplemented with standard
antibiotic and antimycotic solution and 10% FCS. Its identity was verified by genotyping by
the DSMZ (Braunschweig, Germany). Transient transfections were performed with 5 μg of
vector DNA and 20 μl of polyethyleneimine (1 mg/ml, ‘Max’ linear, 40 kDa; Polysciences,
Warrington, PA) per 10 cm2 dish.
Generation of vectors for expression and quantification
The cDNAs of AKT2 and its isoform were cloned into the eukaryotic expression vectors
pcDNA3 and pEBG-2T (which contains a GST fusion tag at the N-terminus of the multiple
cloning site). Suitable restriction sites (BamHI and NotI) were introduced by polymerase
chain reaction, and the cDNAs were introduced in a two-step procedure, first by transferring
the major fragment (BamHI and NotI) and subsequently a minor fragment (NotI) which is
generated by an internal NotI restriction site within the AKT2 cDNA. The vectors were
sequenced to confirm correct placement of the reading frames.
Transcript level quantifications
For assessment of the transcript levels of AKT2 and its isoform in different tissues, we used the
multiple tissue cDNA panels MTC I and MTC II from Clontech (#636742 LOT 5090205 and
#636743 LOT6040176). These panels contain cDNA samples from organ tissues pooled from
several individuals and normalized to at least four housekeeping genes.
TaqMan detection reagents (real-time quantitative PCR (qPCR) primers and probes) were
generated via the FileBuilder software and synthesized by Applied Biosystems. For detection of
the standard AKT2 transcript, a PCR product spanning exons 13–14 was used, while the PCR
product for the AKT2-13a transcript covered exons 13 and the alternative exon 13a. The
probes were spanning the exon boundaries to achieve specificity for cDNA. Control qPCR
reactions with RNA samples which had not been reverse transcribed were performed to vali-
date that no amplification occurs. qPCR reactions contained 15 μl total volume with TaqMan
universal PCR master mix, the assay mixture containing primers and hydrolysis probe, and
1.5 μl sample. Cycling conditions were: 2 min 50˚C, 10 min 95˚C, 60 cycles with 15 s 95˚C and
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60 s 60˚C. The StepOne 2.0 software was used to measure qPCR curves. Calibrations were per-
formed for both transcripts using plasmid dilutions and confirmed comparable amplification
efficiency in both detection reagents.
Protein expression, immunoprecipitation and protein detection
AKT protein was produced by transient transfection of HEK293T cells. For this purpose, cells
were plated into 10 cm dishes at 60% confluency. After three hours, AKT2 expression plasmids
(or a GFP plasmid as transfection control) were transfected into HEK293T cells using 20μl of
1mg/ml PEI (linear, 25 kDa, #23966 Polysciences, USA) with 5 μg plasmid DNA in 1 ml
DMEM. This transfection mixture was added to the cells, and whole cell extracts were pre-
pared after 24 h and analyzed by western blotting. Visualization and quantification were per-
formed using a LAS-4000 (Fuji).
For each immunoprecipitation, 22 μl AKT2-13a antibody solution were incubated with 4 μl
Protein G Dynabead suspension (ThermoFischer Scientific, Waltham, MA) and HEK293
extracts either transfected with AKT2-13a (positive control, 30 μl) or with extract of untreated
cells (1 ml) in a total volume of 1,5 ml in buffer A (50 mM Tris-HCl, pH 7.5, 0,1% β-Mercap-
toethanol, 0,1 mM EGTA) at 4˚C for 1 hour. Washing was performed with buffer A supple-
mented with 500 mM NaCl for three times.
Bioinformatics
MaxEnt scores of AKT2 splicing sites were assessed in January 2019 using the appropriate web
interfaces (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) [16]. Data on
splicing and exon usage of the AKT genes was retrieved from the genotype tissue expression
project (GTEx) site [17].
Protein purification and AKT2 kinase activity assay
GST-AKT2 wt and GST-AKT2-13a were expressed in 10 dishes (145 mm) of HEK293T cells
as detailed above. Cells were harvested after 48 h in lysis buffer (50 mM Trizma pH 7.4, 0.27 M
Sucrose, 1 mM Na-Ortho-Vanadate, 1 mM EDTA, 1 mM EGTA, 10 mM Na-ß-glycerolpho-
sphate, 50 mM NaF, 5 mM Na-pyrophosphate, 1% Triton-x-100) and centrifuged (5.000 g, 15
min). The supernatant was incubated with 0.5 ml Glutathion-Sepharose 4B (GE Healthcare,
Chicago, U.S.A), washed 4 times with 10 ml lysis buffer with 500 mM NaCl, 8 times with 10 ml
buffer A (50 mM Trizma pH 7.4, 0.1 mM EGTA, 0,1% β-Mercaptoethanol), and once with 10
ml buffer A plus 0,26 M Sucrose. Elution was performed with buffer A supplemented with
sucrose and 40 mM glutathione.
Kinase activity was assessed by incubating different amounts of purified AKT2 protein
(100–1000 ng) in 20 μl reactions containing 0.1 mM KK-Crosstide (KKGRPRTSSFAEG; Gen-
Script, Leiden, Netherlands), 50 mM Tris pH 7.4, 10 mM MgCl2, 0.1 mM ATP, 0.05 mg/mL
BSA, 0.1% β-Mercaptoethanol in the presence of 60 nCi [32P]γATP (Perkin Elmer, Waltham,
U.S.A.) for 30 minutes at room temperature. Reactions were terminated with 5 μl of a 1:25
dilution of phosphoric acid 88%. 4 μl of each reaction were applied to p81 paper (Whatman,
Maidstone, U.K.). The paper was washed 4 times for 15 minutes with 50 ml of phosphoric acid
(1:200 of 88%), dried and exposed to a phosphoimager IP screen overnight. Detection was per-
formed with an LAS 9000 imager (Fuji, Japan). Quantifications were done using MultiGauge.
The specific activity of GST-AKT2 was 3.5 U/mg, while the one of GST-AKT2 13a was 0.57 U/
mg (one unit defined as the amount of activity that produces one nmol of product per
minute).
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Results
Alternative splicing in AKT transcripts
While attempting to clone AKT2 by PCR from a cDNA library from cancer-tissue, we unex-
pectedly identified a splice variant of AKT2 that lacked the HM regulatory site. Inspection of
the gene indicated that this alternative mRNA resulted from activation of an alternative exon
(exon 13a) located in intron 13 (IVS13+437; NG_012038.2:55788..55910) (S1 Fig). With a
length of 123 bp, exon 13a has a typical exon size [18] and is framed by canonical splice sites.
The quality of the splice sites, as determined by similarity to consensus splice sites, is below the
average of the other AKT2 exons (S2 Fig). However, they support inclusion in the mRNA,
similarly as has been found for another alternatively spliced gene before [19].
This finding prompted us to analyze the C-terminal splicing of AKT and other kinases con-
taining HM regulatory sites in databases that assemble experimental data for splice variants in
different tissues (Fig 2A and S3 Fig).
Alternative splicing affecting the C-terminal HM regulatory site has previously been
observed in PKCβ, where two different protein isoforms (PKCβI and PKCβII) are generated
by inclusion of two alternative final exons. In the case of PKCβ, the splice variants I and II
both express PKCβ variants that have the TM and HM regulatory sites. Both PKCβ isoforms
differ in their C-terminal tails: isoform I contains 50 residues and isoform II 52 residues,
which both contain an HM motif and a sequence homology of 45% [20]. PKCβI and PKCβII
exhibit different affinities for Ca2+, supporting the idea that the C-terminus of PKCβI and II
also plays a role in the regulation of the C2 domain. However, splice-variant specific biological
Fig 2. Splicing of AKT1-3 genes and predicted proteins of C-terminal splicing events. A. Exons included in the 3’-terminal reference transcripts of
AKT1-3 are shown as black boxes connected by black lines, alternatively spliced exons are shown as white boxes with gray lines. Direction of transcription
is from left to right. The two final exons contain the coding sequence of the turn motif (TM) and the hydrophobic motif (HM) phosphorylation sites. B.
The C-terminal protein sequences of wildtype AKT1/AKT2/AKT3 as well as the predicted protein sequences of alternatively spliced transcripts are shown.
Hydrophobic motif (HM), the turn motif (TM) and the phosphorylation sites are indicated. C. Representation of AKT2 protein (AKT2) and the AKT2-
13a splice variant. The C-terminal fragment containing the HM is lost and replaced by an alternative C-terminus in AKT2-13a (hatched).
https://doi.org/10.1371/journal.pone.0242819.g002
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roles have not yet been revealed [21]. In contrast, other related AGC kinases such as PKCα,
and all SGK, S6K and RSK isoforms did not show splicing of this regulatory domain in the
databases of experimental splice variants. (S3 Fig).
Interestingly, all three AKT genes show alternative splicing that alters the 3’ end of the tran-
script structure. In all three AKT isoforms, the final exons of the genes include a part of the
regulatory domain replacing the region of the hydrophobic motif (HM) phosphorylation sites
(Fig 2A). Indeed, the AKT2 splice variant we found by cloning from a cDNA library had been
experimentally observed and is present in the EST database.
AKT transcripts with alternative splicing in the 3’-end arise either by inclusion of an addi-
tional exon from the final intron (AKT2) or by usage of an alternative final exon located in the
3’ end of the gene (AKT1 and AKT3) (Fig 2B). It is noteworthy that the systematically identi-
fied splicings are of different types in all three AKT genes, suggesting that the spliced variants
emerged independently after the duplication of the AKT gene. Experimental evidence there-
fore shows the existence of alternative transcripts in all three AKT kinases, which would result
in proteins with altered C-termini (Fig 2B).
We selected the transcript AKT2-13a for further characterization. In AKT2-13a, the final
26 residues are substituted by 30 residues (Fig 2C). In contrast to the two alternative C-termi-
nal PKC β isoforms, AKT2-13a does not encode a hydrophobic motif regulatory site in the C-
terminus (Fig 2B).
Detection and quantitation of the novel AKT2-13a transcript
We generated a qPCR assay targeting either the standard transcript (comprising exons 13 and
14) or the alternative transcript (comprising exons 13 and 13a). Quantification in cell lines
(Hela, HuH7, Hep3B, Hep4C, MCF7 and HEK293) demonstrated that the alternative tran-
script AKT2-13a represented between 0.8 and 3.1% of the regular AKT2 transcript. We fur-
thermore investigated the relative quantity of mRNA in human healthy tissues of adult and
fetal origins. The mRNA from regular AKT2 was most abundant in adult tissues of pancreas,
liver, spleen and ovary, while it was much less expressed in brain, colon and small intestine,
with a total difference of greater than tenfold (Fig 3). The quantitation of the alternative tran-
script AKT2-13a confirmed that it is low compared with the abundance of AKT2 in human tis-
sues. However, there was a large difference between tissues: while AKT2-13a corresponded to
3.9% of mRNA of AKT2 in fetal spleen, it was not detectable in several other fetal tissues (Fig
3). On average, the AKT2-13a splice variant corresponded to 1.2% of the standard AKT2 gene,
with the highest relative expression in fetal spleen (3.9%), thyme (2.6%) and heart (2.1%), fol-
lowed by adult lung and testes.
We also tested the abundance of AKT2-13a in six cell lines (HEK293, Huh7, HepB3,
HepC4, MCF). All cells expressed both wildtype AKT2 (S4A Fig) and the alternative variant
AKT2-13a, which represented on average 2% of the wildtype AKT2 (0.8–3.1%), with highest
relative expression in Hela cells (S4B Fig).
The AKT2-13a transcript produces a protein that is phosphorylated at the
activation loop and TM site but less active than AKT2
Since the alternative AKT2 transcript was readily detectable in cell lines and human tissues, we
tested its ability to translate into a protein. The cDNA was cloned into two mammalian expres-
sion vectors, one of which generated a coding sequence for AKT2-13a as a fusion to GST.
For detection of the alternative protein isoform, a rabbit polyclonal antiserum was gener-
ated using a peptide with the novel C-terminal sequence (FREGFLEEEANVSAGRRNDVW-
DASNGRSMA). After transfection of AKT2 and the AKT2-13a isoform in HEK293 cells, both
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protein forms were detectable in a western blot of the whole cell extract by an antibody against
the N-terminus of AKT2 (Fig 4A). As expected from the molecular weight calculation, the
larger AKT2-13a ran higher on the gel than AKT2. The specific antibody for the isoform
AKT2-13a detected major bands only in the lanes corresponding to cells transfected with plas-
mids coding for AKT2-13a (Fig 4B), further confirming the expression and identity of these
signals. The same was true for the GST fusion proteins which were expressed in parallel. How-
ever, while the band strengths were identical in case of the GST fusion proteins, the expression
of AKT2-13a was lower than that of standard AKT2 (Fig 4A). We then asked whether the
splice variant AKT2-13a was phosphorylated in our preparations. Interestingly, we found that
AKT2-13a was phosphorylated at Thr309 at the activation loop, and at Thr452, the TM phos-
phorylation site at similar levels as AKT2 (Fig 4C). As expected, no signal was present for
phospho-Ser474 in AKT2-13a preparations since this residue is lacking in the alternatively
spliced AKT2-13a isoform.
In order to assess endogenous AKT2-13a protein, we investigated its presence in extracts of
untransfected cells, but the anti-serum developed to the AKT2-13a specific sequence did not
detect endogenous protein in cell extract. However, we detected the endogenous expression of
AKT2-13a with the new anti-serum by western-blot after immunoprecipitation of AKT2 using
antibodies that recognize the PH domain (Fig 4D).
In order to assess the kinase activity of the variant AKT2 isoform, we purified both normal
GST-AKT2 and GST-AKT2-13a protein to>95% (S5 Fig). Kinase activity on the peptide sub-
strate Crosstide was assessed at different protein concentrations and was much lower for
AKT2-13a than for wildtype AKT2, with an average relative activity of 16% (Fig 5).
Fig 3. Quantitation of AKT2 and AKT2-13a in adult and fetal human tissues. Both AKT2 and AKT2-13a were
detected by qPCR using specific primers and probes. Top diagram: Expression of AKT2 (standard transcript). Bottom
diagram: Expression of the alternative transcript AKT2-13a in % of AKT2.
https://doi.org/10.1371/journal.pone.0242819.g003
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Discussion
The general model to explain the mechanism of activation of AKT downstream of PI3-kinase,
was depicted almost two decades ago. Interestingly, over the last few years new important
aspects on the mechanism of activation of AKT were described, most notably, the PI3-kinase-
independent activation. The C-terminal region of AKT, comprising the TM and HM sites play
a key regulatory role in the models of AKT activation. The HM directly binds to the PIF-
pocket regulatory site on the small lobe of the catalytic domain, while the phosphorylated TM
site binds to a phosphate-binding site on top of the ATP-binding site, and supports this intra-
molecular binding of the HM to the PIF-pocket in the active conformation (Fig 1). While the
role of the HM on the active structure of AKT is well established, the possible role of the HM
in the docking interaction with the upstream kinase PDK1 in the PI3-kinase independent acti-
vation or in the role of the HM in the inactive structure of AKT is not known. In this context,
we here highlight the existence of splicing variants that replace the C-terminal region of all
three isoforms of AKT which may differ in their regulation. While a possible physiological role
of the AKT2-13a splice variant is not known, the fact that it appeared phosphorylated at the
activation loop (T309) and TM sites suggests that the AKT2-13a is recognized by upstream
kinases. The specific activity of AKT2-13a was 6 times lower, indicating that the amino acid
sequence replacing the hydrophobic motif induced AKT2-13a to behave as expected by AKT2
Fig 4. Protein detection of AKT2 and AKT2-13a. HEK293T cells were transfected with either pcDNA3 vectors containing cDNA coding for
AKT2 and AKT2-13a or with pEBG-2T vectors which encode AKT2-GST fusion proteins. Cells were lysed after 24 hours and protein extracts were
separated by SDS-PAGE followed by blotting and antibody detection with either a AKT2-specific antibody (A) or with an antibody generated to
recognize the novel peptide sequence unique for AKT2-13a (B). The AKT2-specific antibody produced double bands at the height of AKT2, the
lower of which likely represent degradation products. (C). AKT2 (“WT”) and AKT2-13a (“13a”) were transfected in HEK293 cells as detailed in
Materials and Methods. Cells were harvested and protein extracts were prepared. Proteins were separated by SDS-PAGE. Immunoblotting was
performed with detection of AKT2 or AKT2-13a and three antibodies specifically detecting the indicated phosphorylated residues (p-T309 is the
activation loop; p-452 is in the TM; p-474 is in the HM). (D) HEK293T cells were either transfected with pcDNA-AKT2-13a (left, one dish) or left
untransfected (right; thirty dishes). AKT2-13a was immunoprecipitated from protein extracts from these cells using the antibody directed against
the unique C-terminal peptide of AKT2-13a. Washed precipitates were analyzed by SDS-PAGE and western blotting using AKT2 antibody
detection.
https://doi.org/10.1371/journal.pone.0242819.g004
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that is not phosphorylated at the hydrophobic motif. AKT2-13a is well folded and has activity;
therefore its overexpression could deregulate downstream signaling pathways.
In AKT1, AKT2 and AKT3 genes, the resulting AKT splice variant protein isoforms would
retain the major part of the protein: PH-domain and kinase domain remain identical (Fig 2B),
while the C-terminal regulatory domain would be altered such that the coding sequence for
the hydrophobic motif and its adjacent phosphorylation sites are deleted. While the alternative
variants of AKT1 and AKT3 result in proteins with significantly altered molecular weight (Fig
2B), AKT2-13a is most likely to evade detection in standard analyses. However, it is frequent
that researchers overlook additional lower intensity bands of protein kinases observed by west-
ern-blot of crude extracts. Minor bands could be due to post-translational modifications, but
could also originate from the expression of splicing variants. We suggest that proteomic stud-
ies should include the C-terminal AKT splice variants in their analysis.
Besides lacking the HM and the 473 phosphorylation site, AKT2-13a additionally lacks the
terminal serine 477 and tyrosine 479 phosphorylation sites, suggesting that it will also lack reg-
ulation mediated by these sites [4]. The HM of AKT is not bound to the PIF-pocket in the inac-
tive conformation. On the other hand, the non-phosphorylated hydrophobic motif (Phe-xx-
xx-Phe-Ser-Tyr) is unlikely to be free in solution and could have binding partners that are lost
in all AKT splice variants. AKT isoforms have been described to bind to CTMP via its HM
sequence, conferring a negative regulation [22]; such regulation is also expected to be missing
in AKT2-13a.
Interestingly, while the regulation of kinases mediated by the HM is widely present in AGC
kinases, alternative transcripts that lack the HM sequence cannot be observed in many related
kinases (SGK1-3, S6K1/2, PKCα/⍳/z). In PKCβ, two alternative final exons exist, but both con-
tain hydrophobic motifs and their phosphorylation sites. Both protein isoforms (PKCβ I and
PKCβ II) differ in their C-terminal 50/52 amino acids, which share 45% homology, and have
been found to be practically identical in physical and kinetic properties [23]. No differences in
Fig 5. Kinase activity of GST-AKT2-13a in comparison to GST-AKT2 wt. Kinase activity of GST-AKT2-13a was
assessed in comparison to wildtype GST-AKT2 after purification of both proteins (S5 Fig) by measuring the
phosphorylation of Crosstide of different protein amounts (100, 300, 600 and 1000 ng) as detailed in Materials and
Methods. Incorporation of 32P into Crosstide was scored by phosphoimager quantification of radioactive signal (inlay
in graph).
https://doi.org/10.1371/journal.pone.0242819.g005
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biological role(s) has as yet been attributed to these isoforms, which may be attributable to the
partly redundant and overlapping functions of PKC isoforms.
A qPCR specifically distinguishing the alternative transcript AKT2-13a from the normal
AKT2 demonstrated a significantly lower relative abundance of the alternative transcript
AKT2-13a, which was on average 1–2% of standard AKT2. Highest levels were observed in
fetal tissues (roughly 4% in fetal spleen). The level of relative expression of the AKT2-13a tran-
script is low in comparison to the standard transcript. It may be argued that the expression of
the AKT2-13a transcript may be due to the error rate of the mRNA and splicing machinery
that may be related to the overall expression of the AKT2 gene. However, it is noteworthy that
there is up to 5-fold difference in the relative expression between different tissues, suggesting
that there is a tissue-dependent differential splicing of AKT2-13a. Moreover, it is at least curi-
ous that all three AKT isoforms present alternative splicing forms lacking the HM while other
AGC kinases do not show such “errors”.
The novel AKT2-13a form may have a biological function, possibly during embryogenesis,
since its expression was higher in fetal tissues. Alternatively, it is possible that it is a biologically
non-relevant side-product of the splicing. Such side-products arise in normal gene transcrip-
tion, partly due to errors in splice site recognition [14]. In germline mutation detection meth-
ods based on cDNA sequencing, up to 10–25% abnormally spliced products routinely are
considered normal “errors” [24]. The considered intrinsic error rate of the splicing machinery
thus makes it difficult to distinguish potentially relevant transcripts from the noise of by-prod-
uct “errors” [25].
When overexpressed, AKT2-13a accumulated less than the wildtype protein, suggesting a
compromised protein stability. AKT proteins depend on conformational integrity which is in
part conferred by phosphorylation of the TM phosphorylation site T452 [26]. While T452 was
present and phosphorylated in AKT2-13a, its stabilizing effect probably was compromised by
the alternative C-terminal sequence. Interestingly, the C-terminal GST fusion proteins dis-
played identical stabilities with wildtype AKT2 and AKT2-13a, suggesting that the C-terminal
protein extension reverts the destabilizing effect of the non-regular sequence. GST-AKT2-13a
displayed a strongly reduced kinase activity in comparison to GST-AKT2. AKTs have a basal
activity when they are phosphorylated at the turn motif and activation loop sites and further
reach maximal specific activities upon phosphorylation of the hydrophobic motif. The lower
in vitro specific activity of GST-AKT2-13a indicates that the alternative C-terminal sequence
does not bind to the PIF-pocket, or, alternatively, if it binds at the site, it does not promote the
conformational changes that activate the kinase. Moreover, the decreased activity of this splice
variant further confirms the biological relevance of the hydrophobic motif in the regulation of
the specific activity of AKT2.
Taken together, we have investigated an alternative splice variant of human AKT2 that is
predicted to encode a protein with a different C-terminal regulatory tail lacking the hydropho-
bic motif regulatory site. The alternative exon shows no evolutionary conservation. While the
finding that all AKT isoforms form aberrant transcripts with a different C-terminal regulatory
region suggest a potential biological role, our current observations do not unveil a physiologi-
cally relevant regulatory contribution. A physiological or pathophysiological relevance of the
existence of AKT isoforms with a differential C-terminal regulatory region remains to be
established.
Supporting information
S1 Fig. Location and sequence of the alternative exon 13a. The AKT2 gene is shown with all
exons that are spliced into the regular reference sequence, with the exon numbers indicated
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sequence, the invariable dinucleotides (AG..GT) are printed in fat and underlined. The exon
sequence is printed in capitals, non-coding sequence in small lettering.
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S2 Fig. MaxEnt scores for the AKT2 gene. MaxEnt scores are displayed for all 14 regular
AKT2 exons (1–14) as well as for the cryptic exon 13a. 5’-splice sites (boxes) and 3’-splice sites
(circles) of each exon have been connected with a line representing the exon sequence.
(DOCX)
S3 Fig. Location of the hydrophobic motif and splicing in several kinases. Direction of tran-
scription is from left to right. Boxes indicate (alternative) exons, (alternative) splicing events
that have been observed in the genes are indicated by the lines with dots that show which
exons have been observed to be spliced together. The arrow with HM indicates the locations of
the hydrophobic motif. The figures have been adopted from the overview of alternative splic-
ing in different tissues from the GTEx portal.
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S4 Fig. Expression of AKT2 and AKT2-13a in cell lines. Both AKT2 and AKT2-13a were
detected by qPCR using specific primers and probes. A: expression of AKT2 (standard tran-
script) relative to the housekeeping gene GAPDH. B: expression of the alternative transcript
AKT2-13a in % of AKT2.
(DOCX)
S5 Fig. GST-AKT2 and GST-AKT2-13a were expressed in HEK293T cells as detailed in
materials and methods. A. Both proteins were visible in Coomassie staining of cell extract
after SDS-PAGE. B. Western blot detection using anti-GST antibody of the cell extract. C.
Coomassie staining of an SDS-PAGE of purified GST-AKT2 and GST-AKT2-13a (1 μg and
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